Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies.
We are uniting Taconic’s global model production and humanized platforms with TransCure’s expertise in translational in vivo pharmacology, CDX and PDX engraftment, and immune profiling—creating a more connected, seamless experience for researchers.
TransCure will continue to operate under its established brand and leadership, ensuring continuity for customers and partners.
